Synthesis and Small-Animal Positron Emission Tomography Evaluation of [<sup>11</sup>C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood−Brain Barrier
作者:Bernd Dörner、Claudia Kuntner、Jens P. Bankstahl、Marion Bankstahl、Johann Stanek、Thomas Wanek、Gloria Stundner、Severin Mairinger、Wolfgang Löscher、Markus Müller、Oliver Langer、Thomas Erker
DOI:10.1021/jm900940f
日期:2009.10.8
With the aim to develop a positron emission tomography (PET) tracer to assess the distribution of P-glycoprotein (P-gp) at the blood−brain barrier (BBB) in vivo, the potent third-generation P-gp inhibitor elacridar (1) was labeled with 11C by reaction of O-desmethyl 1 with [11C]-methyl triflate. In vitro autoradiography and small-animal PET imaging of [11C]-1 was performed in rats (n = 3), before and
为了开发一种正电子发射断层扫描 (PET) 示踪剂来评估 P-糖蛋白 (P-gp) 在体内血脑屏障 (BBB) 的分布,有效的第三代 P-gp 抑制剂 elacridar ( 1 )通过O-去甲基1与[ 11 C]-三氟甲磺酸甲酯的反应用11 C标记。[ 11 C]- 1 的体外放射自显影和小动物 PET 成像在大鼠 ( n = 3) 中进行,在施用未标记的1之前和之后,以及在野生型Mdr1a/b (-/-)和Bcrp1 (-/-)小鼠 ( n= 3)。在大鼠的 PET 实验中,未标记的1 的给药使大脑活动吸收增加了 5.4 倍,而血液活动水平保持不变。在Mdr1a/b (-/-)小鼠中,与野生型动物相比,大脑活动摄取量高 2.5 倍,而在Bcrp1 (-/-)小鼠中,大脑活动摄取量仅高出 1.3 倍。体外放射自显影显示 63% 的 [ 11 C] -1结合可被过量的未标记1取代。由于用[